A detailed history of Royal London Asset Management LTD transactions in Incyte Corp stock. As of the latest transaction made, Royal London Asset Management LTD holds 174,689 shares of INCY stock, worth $12 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
174,689
Previous 182,852 4.46%
Holding current value
$12 Million
Previous $11.1 Million 4.17%
% of portfolio
0.03%
Previous 0.03%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $467,984 - $560,063
-8,163 Reduced 4.46%
174,689 $11.5 Million
Q2 2024

Aug 07, 2024

BUY
$51.18 - $63.75 $5.65 Million - $7.04 Million
110,360 Added 152.24%
182,852 $11.1 Million
Q1 2024

May 14, 2024

BUY
$56.55 - $66.59 $58,076 - $68,387
1,027 Added 1.44%
72,492 $4.13 Million
Q4 2023

Feb 13, 2024

BUY
$52.16 - $64.19 $343,630 - $422,883
6,588 Added 10.15%
71,465 $4.49 Million
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $104,968 - $119,794
1,817 Added 2.88%
64,877 $3.75 Million
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $54,062 - $66,977
887 Added 1.43%
63,060 $3.93 Million
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $79,359 - $97,191
1,130 Added 1.85%
62,173 $4.49 Million
Q4 2022

Feb 09, 2023

BUY
$67.18 - $84.11 $45,279 - $56,690
674 Added 1.12%
61,043 $4.9 Million
Q3 2022

Nov 14, 2022

SELL
$66.18 - $82.86 $299,398 - $374,858
-4,524 Reduced 6.97%
60,369 $4.02 Million
Q2 2022

Aug 12, 2022

SELL
$66.18 - $83.18 $15,089 - $18,965
-228 Reduced 0.35%
64,893 $4.93 Million
Q1 2022

May 13, 2022

BUY
$66.02 - $79.71 $202,087 - $243,992
3,061 Added 4.93%
65,121 $5.17 Million
Q4 2021

Oct 18, 2022

SELL
$63.34 - $74.11 $40,284 - $47,133
-636 Reduced 1.01%
62,060 $4.56 Million
Q4 2021

Jan 18, 2022

SELL
$63.34 - $74.11 $40,284 - $47,133
-636 Reduced 1.01%
62,060 $4.56 Million
Q3 2021

Oct 18, 2022

SELL
$68.67 - $84.02 $375,006 - $458,833
-5,461 Reduced 8.01%
62,696 $4.31 Million
Q3 2021

Nov 02, 2021

SELL
$68.67 - $84.02 $375,006 - $458,833
-5,461 Reduced 8.01%
62,696 $4.31 Million
Q2 2021

Oct 18, 2022

BUY
$79.87 - $87.53 $260,695 - $285,697
3,264 Added 5.03%
68,157 $5.73 Million
Q1 2021

Oct 17, 2022

BUY
$76.02 - $100.5 $248,129 - $328,032
3,264 Added 5.03%
68,157 $5.54 Million
Q1 2021

Apr 13, 2021

BUY
$76.02 - $100.5 $117,146 - $154,870
1,541 Added 2.31%
68,157 $5.54 Million
Q4 2020

Jan 29, 2021

SELL
$80.74 - $97.7 $244,238 - $295,542
-3,025 Reduced 4.34%
66,616 $5.79 Million
Q2 2020

Jul 31, 2020

SELL
$74.18 - $108.93 $319,419 - $469,052
-4,306 Reduced 5.82%
69,641 $7.14 Million
Q2 2019

Jul 31, 2019

SELL
$73.52 - $88.7 $85,503 - $103,158
-1,163 Reduced 1.55%
73,947 $6.28 Million
Q1 2019

Apr 30, 2019

SELL
$63.56 - $88.17 $4.38 Million - $6.08 Million
-68,985 Reduced 47.87%
75,110 $0
Q4 2018

Jan 29, 2019

BUY
$58.5 - $69.94 $836,959 - $1 Million
14,307 Added 11.02%
144,095 $8.97 Million
Q3 2018

Nov 08, 2018

SELL
$61.75 - $74.23 $977,996 - $1.18 Million
-15,838 Reduced 10.88%
129,788 $0
Q2 2018

Sep 19, 2018

BUY
$60.85 - $83.98 $8.86 Million - $12.2 Million
145,626 New
145,626 $9.76 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Royal London Asset Management LTD Portfolio

Follow Royal London Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.